513 related articles for article (PubMed ID: 33416134)
1. Nanobodies targeting immune checkpoint molecules for tumor immunotherapy and immunoimaging (Review).
Yu S; Xiong G; Zhao S; Tang Y; Tang H; Wang K; Liu H; Lan K; Bi X; Duan S
Int J Mol Med; 2021 Feb; 47(2):444-454. PubMed ID: 33416134
[TBL] [Abstract][Full Text] [Related]
2. Anti-CTLA-4 nanobody as a promising approach in cancer immunotherapy.
Babamohamadi M; Mohammadi N; Faryadi E; Haddadi M; Merati A; Ghobadinezhad F; Amirian R; Izadi Z; Hadjati J
Cell Death Dis; 2024 Jan; 15(1):17. PubMed ID: 38191571
[TBL] [Abstract][Full Text] [Related]
3. Clinical Challenges of Immune Checkpoint Inhibitors.
de Miguel M; Calvo E
Cancer Cell; 2020 Sep; 38(3):326-333. PubMed ID: 32750319
[TBL] [Abstract][Full Text] [Related]
4. Nanobodies in cell-mediated immunotherapy: On the road to fight cancer.
Maali A; Gholizadeh M; Feghhi-Najafabadi S; Noei A; Seyed-Motahari SS; Mansoori S; Sharifzadeh Z
Front Immunol; 2023; 14():1012841. PubMed ID: 36761751
[TBL] [Abstract][Full Text] [Related]
5. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
6. Nanobodies in cytokine‑mediated immunotherapy and immunoimaging (Review).
Zhang X; Wang J; Tan Y; Chen C; Tang S; Zhao S; Qin Q; Huang H; Duan S
Int J Mol Med; 2024 Feb; 53(2):. PubMed ID: 38063273
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
Hargadon KM; Johnson CE; Williams CJ
Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
[TBL] [Abstract][Full Text] [Related]
8. Angiogenic biomolecules specific nanobodies application in cancer imaging and therapy; review and updates.
Shoari A; Tahmasebi M; Khodabakhsh F; Cohan RA; Oghalaie A; Behdani M
Int Immunopharmacol; 2022 Apr; 105():108585. PubMed ID: 35131732
[TBL] [Abstract][Full Text] [Related]
9. Nanobody-based cancer therapy of solid tumors.
Kijanka M; Dorresteijn B; Oliveira S; van Bergen en Henegouwen PM
Nanomedicine (Lond); 2015 Jan; 10(1):161-74. PubMed ID: 25597775
[TBL] [Abstract][Full Text] [Related]
10. Nanobodies as versatile tools: A focus on targeted tumor therapy, tumor imaging and diagnostics.
Al-Baradie RS
Hum Antibodies; 2020; 28(4):259-272. PubMed ID: 32831197
[TBL] [Abstract][Full Text] [Related]
11. Editorial: Nanobody-based cancer immunotherapy and immunoimaging.
Jafari M; Maali A; Shokrgozar MA; Sharifzadeh Z
Front Immunol; 2023; 14():1213386. PubMed ID: 37261357
[No Abstract] [Full Text] [Related]
12. Nanobodies: A Game-Changer in Cell-Mediated Immunotherapy for Cancer.
Mustafa MI; Mohammed A
SLAS Discov; 2023 Dec; 28(8):358-364. PubMed ID: 37634615
[TBL] [Abstract][Full Text] [Related]
13. Nanobody-based CTLA4 inhibitors for immune checkpoint blockade therapy of canine cancer patients.
Marable J; Ruiz D; Jaiswal AK; Bhattacharya R; Pantazes R; Agarwal P; Suryawanshi AS; Bedi D; Mishra A; Smith BF; Sandey M
Sci Rep; 2021 Oct; 11(1):20763. PubMed ID: 34675296
[TBL] [Abstract][Full Text] [Related]
14. Nanobodies targeting the interaction interface of programmed death receptor 1 (PD-1)/PD-1 ligand 1 (PD-1/PD-L1).
Wen B; Zhao L; Wang Y; Qiu C; Xu Z; Huang K; Zhu H; Li Z; Li H
Prep Biochem Biotechnol; 2020; 50(3):252-259. PubMed ID: 31799894
[TBL] [Abstract][Full Text] [Related]
15. Development of Cancer Immunotherapy Targeting the PD-1 Pathway.
Kamimura N; Wolf AM; Iwai Y
J Nippon Med Sch; 2019; 86(1):10-14. PubMed ID: 30918149
[TBL] [Abstract][Full Text] [Related]
16. Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment.
Wang J; Kang G; Yuan H; Cao X; Huang H; de Marco A
Front Immunol; 2021; 12():838082. PubMed ID: 35116045
[TBL] [Abstract][Full Text] [Related]
17. Cytokines as potential combination agents with PD-1/PD-L1 blockade for cancer treatment.
Rahimi Kalateh Shah Mohammad G; Ghahremanloo A; Soltani A; Fathi E; Hashemy SI
J Cell Physiol; 2020 Jul; 235(7-8):5449-5460. PubMed ID: 31970790
[TBL] [Abstract][Full Text] [Related]
18. The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer.
Alemohammad H; Najafzadeh B; Asadzadeh Z; Baghbanzadeh A; Ghorbaninezhad F; Najafzadeh A; Safarpour H; Bernardini R; Brunetti O; Sonnessa M; Fasano R; Silvestris N; Baradaran B
Biomed Pharmacother; 2022 Feb; 146():112516. PubMed ID: 34906767
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
[TBL] [Abstract][Full Text] [Related]
20. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy.
Tang T; Huang X; Zhang G; Hong Z; Bai X; Liang T
Signal Transduct Target Ther; 2021 Feb; 6(1):72. PubMed ID: 33608497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
